“Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest”, J of Skin, vol. 7, no. 2, p. s143, Mar. 2023, doi: 10.25251/skin.7.supp.143.